Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2008 Apr;7(4):972-9. doi: 10.1158/1535-7163.MCT-07-2141. Epub 2008 Mar 28.


Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.

Lubet RA, Steele VE, DeCoster R, Bowden C, You M, Juliana MM, Eto I, Kelloff GJ, Grubbs CJ.

Carcinogenesis. 1998 Aug;19(8):1345-51.


Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96.


Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.

Lubet RA, Christov K, Nunez NP, Hursting SD, Steele VE, Juliana MM, Eto I, Grubbs CJ.

Carcinogenesis. 2005 Feb;26(2):441-8. Epub 2004 Dec 9.


Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.

Grubbs CJ, Lubet RA, Atigadda VR, Christov K, Deshpande AM, Tirmal V, Xia G, Bland KI, Eto I, Brouillette WJ, Muccio DD.

Carcinogenesis. 2006 Jun;27(6):1232-9. Epub 2005 Dec 12.


Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.


Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.

Van Ginckel R, Janssens B, Callens M, Goeminne N, Wouters L, De Coster R.

Cancer Chemother Pharmacol. 1996;38(1):21-8.


Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole.

Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, Kelloff G, Lubet R.

Breast Cancer Res Treat. 2000 Mar;60(2):117-28.


Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M.

Cancer Prev Res (Phila). 2012 Feb;5(2):248-59. doi: 10.1158/1940-6207.CAPR-10-0363. Epub 2011 Oct 7.


Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.

Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, Ericson ME, Bode AM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1190-7. doi: 10.1158/1940-6207.CAPR-10-0330. Epub 2011 Jul 26.


Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.

Cancer Res. 1998 Feb 1;58(3):479-84.


Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2006 Apr;5(4):1073-8.


Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.

Rodríguez-Burford C, Lubet RA, Eto I, Juliana MM, Kelloff GJ, Grubbs CJ, Steele VE.

Carcinogenesis. 1999 Jan;20(1):71-6.


9cUAB30, an RXR specific retinoid, and/or tamoxifen in the prevention of methylnitrosourea-induced mammary cancers.

Grubbs CJ, Hill DL, Bland KI, Beenken SW, Lin TH, Eto I, Atigadda VR, Vines KK, Brouillette WJ, Muccio DD.

Cancer Lett. 2003 Nov 10;201(1):17-24.


Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.


Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea.

Knott KK, McGinley JN, Lubet RA, Steele VE, Thompson HJ.

Breast Cancer Res Treat. 2001 Dec;70(3):171-83.


Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.

Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC.

Anticancer Res. 1992 Jul-Aug;12(4):1147-53.


Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk